Journal
CANCER
Volume 115, Issue 18, Pages 4104-4109Publisher
WILEY
DOI: 10.1002/cncr.24466
Keywords
neoadjuvant chemotherapy; bladder cancer; pathologic complete response; overall survival
Categories
Funding
- National Cancer Institute, Department of Health and Human Services [CA32102, CA38926, CA21115, CA35421, CA46441, CA22433, CA42777, CA58861, CA59416, CA46282, CA27057, CA14028, CA46113, CA20319, CA46136, CA45377, CA128567, CA45560, CA35431, CA32734, CA35261, CA35090, CA16385, CA58882, CA76447, CA46368, CA68183, CA28862, CA58415, CA35281, CA63844, CA35192]
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- AstraZeneca
- Novartis
- Celgene
- Cytogen
Ask authors/readers for more resources
BACKGROUND: In a retrospective study of Southwestern Oncology Group (SWOG)-S8710/INT-0080 (radical cystectomy [RC] alone vs 3 cycles of neoadjuvant chemotherapy [NC] with methotrexate, vinblastine, doxorubicin, and cisplatin before RC for bladder cancer), factors found to be associated with improved overall survival (OS) included pathologic complete response, defined as PO: treatment with NC; completion of RC with negative surgical margins; and >= 10 pelvic lymph nodes (LNs) removed, METHODS: The authors used stratified Cox regression to retrospectively study the association of quality of pathologic response after RC with OS in the subset of S8710 patients who received NC and RC with negative surgical margins. RESULTS: Of 154 patients who received NC, 68 (44.2%) were
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
